“Our product launches will be ramping through the year, so we expect revenue growth to accelerate through the quarters as well.”

In context

“nce is also evident in the decision by our Board to increase our dividend for the 47th consecutive year, which we announced this morning. The yield from our growing dividend is an important component of the total return we generate for our shareholders. It's worth noting that we've been able to grow our dividend by 30% over the past five years and 130% over the past decade. Now turning to our guidance. After six quarters in a row, we firmly established a track record of delivering durable mid-single-digit revenue growth. And as Geoff mentioned, we're at the beginning stages of many new product cycles that enable confidence in our top line. Given this backdrop, we'd have you start the year modeling our fiscal '25 organic revenue growth at 4% to 5% including 4% to 4.5% in the first quarter. Our product launches will be ramping through the year, so we expect revenue growth to accelerate through the quarters as well. By segment, we'd expect our three portfolios to be roughly aligned with the corporate average and Diabetes to grow above the corporate average. Our organic growth guidance continues to exclude revenue reported in other as well as foreign exchange. And I direct you to the guidance slide in our earnings presentation for additional details. Regarding currency, based on recent rates, we would see a full year unfavorable impact to revenue in the range of $275 million to $375 million, including an unfavorable impact of $85 million to $135 million in the first quarter. Down the P&L, we expect expansion in our operating margin as we drive efficiencies in our overhead spend. At the same time, we continue to appropriately invest in R&D to drive future growth. Taking all of this together, we're guid”